HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3β/β-catenin pathway.

Abstract
Recently, tumor initiating cells are considered as the central role of tumorigenicity in hepatocellular carcinoma. Enediyne anticancer antibiotic lidamycin with great potential antitumor activity is currently evaluated in Phase II clinical trials. In this study, we evaluated the effect of lidamycin on tumor initiating cells of hepatocellular carcinoma Huh7 and identified the potential mechanism. Flow cytometry analysis and sorting assay, surface marker assay, sphere formation assay, and aldefluor assay were used to evaluate the effect of lidamycin on Huh7 tumor initiating cells in vitro. To investigate the potential mechanism, the activity of GSK3β/β-catenin pathway was detected by Western blot and T cell factors transcriptional activity assay. Subcutaneous tumor model in nude mice was used to observe in vivo effect of lidamycin on Huh7 cells. Lidamycin decreased the proportion of EpCAM+ cells and the expression of EpCAM protein. Lidamycin inhibited sphere formation of sorted EpCAM+ cells in 7 d, and of parental cells in three serial passages. The population of aldehyde dehydrogenase-positive cells was reduced by lidamycin. In addition, lidamycin restrained tumor volume and incidence in vivo. Lidamycin activated GSK3β, and degraded the activity of β-catenin. Consequently, transcriptional activity of β-catenin/T cell factors was decreased. In brief, these results suggest that lidamycin suppressed Huh7 tumor initiating cells via GSK3β/β-catenin pathway. These findings reveal the potential mechanism of lidamycin on tumor initiating cells and the benefit for further clinical evaluation.
AuthorsYi Chen, Dongke Yu, Caixia Zhang, Boyang Shang, Hongwei He, Jinjing Chen, Hao Zhang, Wuli Zhao, Zhen Wang, Xiaoyu Xu, Yongsu Zhen, Rong-guang Shao
JournalMolecular carcinogenesis (Mol Carcinog) Vol. 54 Issue 1 Pg. 1-8 (Jan 2015) ISSN: 1098-2744 [Electronic] United States
PMID23857500 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 Wiley Periodicals, Inc.
Chemical References
  • Aminoglycosides
  • Antibiotics, Antineoplastic
  • Enediynes
  • beta Catenin
  • C 1027
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Glycogen Synthase Kinase 3
Topics
  • Aminoglycosides (pharmacology)
  • Animals
  • Antibiotics, Antineoplastic (pharmacology)
  • Carcinoma, Hepatocellular (drug therapy, pathology)
  • Cell Line, Tumor
  • Enediynes (pharmacology)
  • Glycogen Synthase Kinase 3 (metabolism)
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Liver Neoplasms (drug therapy, pathology)
  • Liver Neoplasms, Experimental
  • Mice
  • Mice, Nude
  • Neoplastic Stem Cells (drug effects)
  • Signal Transduction (drug effects)
  • Xenograft Model Antitumor Assays
  • beta Catenin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: